Reasons for clinical ineligibility to participate by site (proportion of total ineligible (%)).

<p>Reasons for clinical ineligibility to participate by site (proportion of total ineligible (%)).</p

HINTS Study Sites.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0039530#pone.0039530-Health1" target="_blank">[1]</a> Health Protection Agency. HIV in the United Kingdom 2010. Health Protection Agency; 2010 [accessed 24th January 2011]; Available from: <a href="http://www.hpa.org.uk/Publications/InfectiousDiseases/HIVAndSTIs/1011HIVUK2010Report/" target="_blank">http://www.hpa.org.uk/Publications/InfectiousDiseases/HIVAndSTIs/1011HIVUK2010Report/</a>.</p

Multivariable logistic regression model showing significant independent predictors of HIV test uptake in patients who were offered the test.

<p> <i>(n = 6194; adjusted for ethnicity, and other variables in the model, and stratified by site).</i></p

Coverage, uptake and seropositivity of routine offer of HIV test across the four sites.

<p>Coverage, uptake and seropositivity of routine offer of HIV test across the four sites.</p

Multivariable logistic regression model showing potential predictors of HIV test uptake in patients who completed the questionnaire.

<p> <i>(n = 1003; adjusted for age, ethnicity and other variables in the model, and stratified by site; MSM = men who have sex with men).</i></p

Staff attitudes and barriers to the provision of HIV tests in non-specialist settings.

<p>Staff attitudes and barriers to the provision of HIV tests in non-specialist settings.</p

OPAL-HIV-Gag(c) and CMV peptide pool specific CD4+ T-cell responses before and after vaccination.

<p>All six subjects from each dose group (0 mg, 12 mg and 24 mg) were tested for OPAL-HIV-Gag(c) specific or no peptide (mock) responses by ICS shown as IFNγ+/MIP1β+ double positive CD4+ T-cells processed from frozen PBMCs derived at week 0, 13 and 14 after first vaccination expressed as the mean of triplicate stimulations (A) and expressed as median values within dose groups with error bars representing inter quartile ranges for OPAL-HIV-Gag(c) (B) and for CMV specific CD4+ T-cell responses (C).</p

Transient and treatment specific lymphopenia after vaccination.

<p>Total lymphocyte counts were performed before, during and at follow up after vaccination as indicated on the x-axis for the three groups (0 mg, 12 mg and 24 mg) and shown as mean values (million lymphocytes per ml whole blood) for the 6 subjects within each group with normal high and low values for HIV positive individuals indicated by dotted lines (A). Arrows indicate vaccinations. The percent (%) change of lymphocyte count from baseline (week 0) is shown as mean values for the three dose groups with error bars representing standard error of mean (SEM) (B). Only one subject (024) was available for the 48 mg dose group at week 0 and 4.</p

OPAL-HIV-Gag(c) peptide pool specific responses before and after vaccination.

<p>All six subjects from each dose group (0 mg, 12 mg and 24 mg) were tested for OPAL-HIV-Gag(c) specific or no peptide (mock) responses by IFNγ ex vivo ELIspot performed from fresh cells at week 0, 10, 12, 13, 14 and 16 after first vaccination expressed as the mean SFU per million cells of triplicate stimulations (A) and expressed as median values within dose groups with error bars representing inter quartile ranges (B).</p

OPAL-HIV-Gag(c) and CMV peptide pool specific CD8+ T-cell responses before and after vaccination.

<p>All six subjects from each dose group (0 mg, 12 mg and 24 mg) were tested for OPAL-HIV-Gag(c) specific or no peptide (no stimulation) responses by ICS shown as IFNγ+/MIP1β+ double positive CD8+ T-cells processed from frozen PBMCs derived at week 0, 13 and 14 after first vaccination expressed as the mean of triplicate stimulations (A) and expressed as median values within dose groups with error bars representing inter quartile ranges for OPAL-HIV-Gag(c) (B) and for CMV specific CD8+ T-cell responses (C).</p